Listen
Reason for request
Inclusion on the list of medicines approved for hospital use in the indication extension “in combination with melphalan and prednisone for the treatment of patients with previously untreated multiple myeloma, who are not eligible for high-dose chemotherapy with bone marrow transplantation”.
-
Clinical Benefit
| Substantial |
The actual benefit is substantial. |
Clinical Added Value
| moderate |
VELCADE, when added to the combination of melphalan and prednisone, provides a moderate (level III) improvement in actual benefit with respect to efficacy when compared with the combination of melphalan and prednisone alone in the first-line treatment of patients with multiple myeloma who are not eligible for high-dose chemotherapy with bone marrow transplantation. |
English version
Contact Us
Évaluation des médicaments
